Literature DB >> 35788171

LncRNAs in breast cancer: a link to future approaches.

Nikolaos Sideris1, Paola Dama2, Salih Bayraktar2, Thomas Stiff2, Leandro Castellano3,4.   

Abstract

Breast cancer affects millions of women each year. Despite recent advances in targeted treatments breast cancer remains a significant threat to women's health. In recent years the development of high-throughput sequencing technologies has advanced the field of transcriptomics shedding light on the role of non-coding RNAs (ncRNAs), including long ncRNAs (lncRNAs), in human cellular function and disease. LncRNAs are classified as transcripts longer than 200nt with no coding potential. These transcripts constitute a diverse group of regulatory molecules essential to the modulation of crucial cellular processes, which dysregulation of leads to disease. LncRNAs exert their regulatory functions through their sequences and by forming complex secondary and tertiary structures that interact with other transcripts, chromatin and/or proteins. Numerous studies have provided evidence of the involvement of LncRNAs in tumor development and disease progression. They possess multiple characteristics that make them novel therapeutic and diagnostic targets. Indeed, the discovery of a novel mechanism by which lncRNAs associated with proteins can induce the formation of phase-separated droplets broadens our understanding of the spatiotemporal control of cellular processes and opens up developing a new treatment. Nevertheless, the role and the molecular mechanisms of many lncRNAs in the regulation of cellular processes and cancer still remain elusive. This is due to the absence of a thorough characterization of the regulatory role of their loci and the functional impact of their aberrations in cancer biology. Here, we present some of the latest advances concerning the role of LncRNAs in breast cancer.
© 2022. Crown.

Entities:  

Year:  2022        PMID: 35788171     DOI: 10.1038/s41417-022-00487-w

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  32 in total

Review 1.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.

Authors:  Sunil Badve; David J Dabbs; Stuart J Schnitt; Frederick L Baehner; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Jocelyne Jacquemier; Sunil R Lakhani; José Palacios; Emad A Rakha; Andrea L Richardson; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Britta Weigelt; Ian O Ellis; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2010-11-12       Impact factor: 7.842

2.  Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.

Authors:  John L Rinn; Michael Kertesz; Jordon K Wang; Sharon L Squazzo; Xiao Xu; Samantha A Brugmann; L Henry Goodnough; Jill A Helms; Peggy J Farnham; Eran Segal; Howard Y Chang
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

Review 3.  Alternative splicing of lncRNAs in human diseases.

Authors:  Jiaxi Chen; Yawen Liu; Jingyu Min; Huizhi Wang; Feifan Li; Chunhui Xu; Aihua Gong; Min Xu
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

4.  SCIRT lncRNA Blocks the Shot of Breast Cancer Cells Self-Renewal Mechanism.

Authors:  Barbara Pardini; Mihnea P Dragomir
Journal:  Cancer Res       Date:  2021-02-01       Impact factor: 12.701

Review 5.  Breast cancer intrinsic subtype classification, clinical use and future trends.

Authors:  Xiaofeng Dai; Ting Li; Zhonghu Bai; Yankun Yang; Xiuxia Liu; Jinling Zhan; Bozhi Shi
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

Review 6.  The rise of regulatory RNA.

Authors:  Kevin V Morris; John S Mattick
Journal:  Nat Rev Genet       Date:  2014-04-29       Impact factor: 53.242

Review 7.  Breast cancer: origins and evolution.

Authors:  Kornelia Polyak
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

8.  SCIRT lncRNA Restrains Tumorigenesis by Opposing Transcriptional Programs of Tumor-Initiating Cells.

Authors:  Sladjana Zagorac; Alex de Giorgio; Justin Stebbing; Leandro Castellano; Aleksandra Dabrowska; Mark Kalisz; Nuria Casas-Vila; Paul Cathcart; Angela Yiu; Silvia Ottaviani; Neta Degani; Ylenia Lombardo; Alistair Tweedie; Tracy Nissan; Keith W Vance; Igor Ulitsky
Journal:  Cancer Res       Date:  2020-11-10       Impact factor: 12.701

9.  SCIRT lncRNA slows the formation of tumour initiating cells in breast cancer.

Authors:  Alex de Giorgio; Leandro Castellano
Journal:  Oncoscience       Date:  2021-06-03

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.